- Home
- KZIA vs CNTB Comparison
KZIA vs CNTB Comparison
Compare KZIA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | CNTB |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.6M | 140.4M |
| IPO Year | 2002 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KZIA | CNTB |
|---|---|---|
| Price | $7.39 | $0.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $28.76 | $6.00 |
| AVG Volume (30 Days) | 199.6K | ★ 723.2K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | $11,287.85 |
| Revenue Next Year | N/A | $74.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.86 | $0.68 |
| 52 Week High | $17.40 | $3.82 |
Technical Indicators
Market Signals| Indicator | KZIA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 37.86 | 34.78 |
| Support Level | $6.72 | N/A |
| Resistance Level | $14.85 | $2.62 |
| Average True Range (ATR) | 0.63 | 0.06 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 19.91 | 7.76 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.